Drugs / Bemosuzumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07010393 | Jul 2025 → Dec 2027 expected | thyroid tumor | Fujian Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bemosuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07010393 ↗ |
| Route | Intravenous | “China PD-L1 antibody bemosuzumab 900 mg IV every 2 weeks (14-day cycle).” NCT07010393 ↗ |